Assessment of Maternal and Fetal Serum Biomarkers in Women With Pre-eclampsia

Assessment of Maternal and Fetal Serum Soluble Fms-like Tyrosine Kinase-1, Seromucoid, and Protein-bound Hexose in Women With Pre-eclampsia: A Case-control Study

The findings of markers of placental dysfunction in women with preeclampsia may suggest that these biomarkers may be useful tools for early detection of preeclampsia

Preeclampsia is a pregnancy-specific hypertension illness that is characterized by widespread maternal endothelial dysfunction and appears to be a systemic syndrome that originates in the placenta. Through binding to and blocking the interaction of placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) with their receptors Flt1, soluble fms-like tyrosine kinase (sFlt1) functions as an antagonist of these growth factors. Most seromucoid and protein-bound hexose are released during an acute phase and are inflammatory glycoproteins. Hepatocytes in the liver, which are highly sensitive to stress, increase and leak into the bloodstream during any disease state. It is a time when the placenta demands more vascular development. In order to identify and explain the differences in sFLT-1, VEGF, PlGF levels, and inflammatory biomarker responses. Current study will investigate the differences in blood level of sFLT-1, VEGF, PLGF, Seromucoid and protein-bound hexose inflammatory biomarkers between those with PE (cases) and healthy pregnant women (controls).

Inclusion Criteria:

• Age group 18-45 years
• Gestational age of 26-41 weeks at the time of diagnosis for preeclampsia
• Delivered vaginally or abdominally
• Being of any parity (para 1 and more)
• Pregnancy being singleton or multiple pregnancies
• Willingness to provide informed consent

Exclusion Criteria:

• Pregnant woman having chronic hypertension
• Having Diabetes mellitus
• The lady on medications that can affect inflammatory markers or blood pressure
• Pregnant with fetal anomalies
• Refused to involve in the research